Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: KEGG:D02027 (Tranilast)
 205 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

The effects of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast), a blocker for histamine release from mast cells, on rabbit blood platelet functions were investigated. Tranilast inhibited dose dependently both the release of a lysozomal enzyme, beta-N-acetylglucosaminidase, and aggregation of washed rabbit platelets stimulated by thrombin and collagen. The IC50 was suspected to be 164 +/- 50 microM. The data suggest that Tranilast may be used as an anti-platelet agent in addition to an anti-allergic one.
 ...
PMID:Anti-platelet action of an anti-allergic agent, N-(3',4'-dimethoxycinnamoyl)anthranilic acid (tranilast). 241 48

The molecular basis for the inhibitory action of the antiatopic drug, N-(3',4'-dimethoxycinnamoyl)anthranilic acid (Tranilast), on the thrombin-induced release of a lysosomal enzyme, beta-N-acetylglucosaminidase, from washed rabbit platelets was investigated. Tranilast dose dependently increased cyclic AMP and cyclic GMP levels in thrombin-stimulated platelets, parallel with the inhibition of beta-N-acetylglucosaminidase release. There was no significant effect of Tranilast on adenylate or guanylate cyclase activity. Tranilast inhibited the activity of cyclic AMP and cyclic GMP phosphodiesterases in a cell-free system. The data suggest that the inhibitory action of Tranilast on the release reaction in platelets was due at least in part to inhibition of cyclic nucleotide phosphodiesterases followed by an elevation of cyclic AMP and cyclic GMP levels.
 ...
PMID:The mechanism for the inhibitory action of N-(3',4'-dimethoxycinnamoyl)anthranilic acid (tranilast) on the release reaction in platelets. 246 71